PRESSENSA®

Quality Dermal Solutions

PUBLIC TECHNICAL DATASHEET

SKU: PRS-3178 | v1.0.0 | EN

Etternity Dermal S.L. | Madrid, Spain

WhitExtreme

Line: Professional Cosmetics | Presentation: Professional cabin dermocosmetic format

Lightening cream for daily use with a light texture. It provides deep hydration, helps to prevent the formation of spots on the face. Reduces stains caused by age and leaves a glowing complexion.



KEY ACTIVE INGREDIENTS

- AXOLIGHT (TM) - Faster than Arbutine. Powerful skin lightener enriches in the extract of oligosaccharides derived from wheat bran. The active particle found in the material is arabinoxylose. Axolight inhibits the process of melanogenesis by inhibiting tyrosinase which is the precursor of melanin. Such an effect translates directly into skin illumination
- NIACINAMIDE - Unify the skin tone
- VITAMIN A - Fewer wrinkles and more collagen Has the ability to regulate cell proliferation and increase the production of collagen and elastin and vitamin E with its anti-oxidant properties and regenerating.
- VITAMIN E Rejuvenates tired skin and prevents ageing spots

COSMETIC / CLINICAL INDICATIONS

- WhitExtreme
- Lightening cream for daily use with a light texture. It provides deep hydration, helps to prevent the formation of spots on the face. Reduces stains caused by age and leaves a glowing complexion.
- BELLIDES (TM) Contains skin brighteners assets, derivatives of Bellis perennis flowers. Its action is based on reducing the activity of melanin, which provides that even pigmentation and age spots be less visible.
- ROSEHIP OIL - Elimination of dark spots

REGULATORY & QUALITY GOVERNANCE

Status: APPROVED (2026-11-26) | Reviewer: Etternity Dermal, S.L. · Technical Direction
Regulatory Classification: Cosmetic - Reg. (EC) 1223/2009 | Audience: Professional Cabin & Home Care
Claims / Regulatory Standard: Regulation (EC) No 1223/2009 · Regulation (EU) No 655/2013 | Markets: EU, MENA, LATAM, CIS
RESTRICTED DOCUMENTATION NOTICE: Full clinical injection/needling protocols, SDS and regulatory dossiers are excluded from public builds and provided strictly via controlled access.